Swiss pharmaceutical giant Novartis has restrained a local pharma company from making anti-diabetes drug by approaching a court because the MNC had patented the drug and is enjoying monopoly over its production and sale.
Paycom Software, Inc. (NYSE: PAYC) surged 3.15% to $23.91. The volume of Paycom Software shares traded 2633% higher than normal. Paycom Software announced the pricing of a secondary public offering of 5,585,000 shares of its common stock by...
The Delhi High Court has barred generic drugmaker Cipla Ltd from making or selling a cheaper copy of Novartis AG's respiratory drug Onbrez domestically, citing infringement of patents held by the Swiss company.
Novartis AG (NVS) traded between $95.73 and $96.81 before closing at $96.12 Friday and presents some attractive trading opportunities today. MarketIntelligenceCenter.com’s patented algorithms selected a Apr. '15 $95.00 covered call for a net...
U.K. officials have decided which drugs to toss off the Cancer Drug Fund, which pays for drugs rejected by cost-effectiveness gatekeepers. Reportedly, Novartis, Sanofi and Eisai treatments are among them.
A group of FDA advisers unanimously recommended approval for Novartis' knockoff of a blockbuster Amgen treatment, clearing the way for what would be the first U.S. approval of a copycat biologic medicine.
Oops! Unable to complete your request. Please refresh your browser.